Definition | |
---|---|
Inclusion criteria | |
Age ≥ 18 years | |
Able to provide informed consent | |
Able and willing to follow instructions for use of automated BP machine and app-based system | |
Chronic kidney disease | Abnormalities of kidney structure or function (either reduced GFR < 90 ml/min/1.73 m2, albuminuria or proteinuria) present prior to pregnancy |
Autoimmune disorder | Diagnosis of an autoimmune condition such as systematic lupus erythematosus prior to pregnancy |
Type 1 or type 2 diabetes mellitus | |
Chronic hypertension | Systolic BP > 140 mmHg or diastolic BP > 90 mmHg on at least 2 occasions prior to 20 weeks’ gestation |
Previous pregnancy complicated by HDP or diagnosis of gestational hypertension this pregnancy | Previous HDP includes chronic hypertension, gestational hypertension, preeclampsia, or preeclampsia superimposed on chronic hypertension Gestational hypertension (Systolic BP > 140 mmHg or diastolic BP > 90 mmHg on at least 2 occasions after 20 weeks’ gestation) |
Confirmation of viable intrauterine pregnancy on dating scan | |
IVF pregnancy | |
High-risk for developing preeclampsia on first-trimester screening | Reported risk of < 1:100 of developing preeclampsia on commercially available combined first-trimester screening tests |
Before 28 weeks gestation | |
Exclusion criteria | |
Participants who have signs of preeclampsia on initial evaluation | Preeclampsia (BP reading > 140 mmHg and/or 90 mmHg on at least 2 occasions after 20 weeks’ gestation accompanied by evidence of end-organ involvement) |
Multifoetal pregnancy | |
Lethal foetal abnormality | Lethal foetal chromosomal, genetic or morphological abnormality detected on screening tests |
Inability to access or use the app-based system | |
Unable to consent | |
Non-English speaking background not supported by the mobile application |